Cargando…

Claudin-Low Breast Cancer; Clinical & Pathological Characteristics

Claudin-low breast cancer is a molecular type of breast cancer originally identified by gene expression profiling and reportedly associated with poor survival. Claudin-low tumors have been recognised to preferentially display a triple-negative phenotype, however only a minority of triple-negative br...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dias, Kay, Dvorkin-Gheva, Anna, Hallett, Robin M., Wu, Ying, Hassell, John, Pond, Gregory R., Levine, Mark, Whelan, Tim, Bane, Anita L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5207440/ https://www.ncbi.nlm.nih.gov/pubmed/28045912 http://dx.doi.org/10.1371/journal.pone.0168669

Ejemplares similares

A Gene Signature for Predicting Outcome in Patients with Basal-like Breast Cancer
por: Hallett, Robin M., et al.
Publicado: (2012)

Identification and evaluation of network modules for the prognosis of basal-like breast cancer
por: Hallett, Robin M., et al.
Publicado: (2015)

Serotonergic system antagonists target breast tumor initiating cells and synergize with chemotherapy to shrink human breast tumor xenografts
por: Gwynne, William D, et al.
Publicado: (2017)

The effects of lymph node status on predicting outcome in ER+ /HER2- tamoxifen treated breast cancer patients using gene signatures
por: Cockburn, Jessica G., et al.
Publicado: (2016)

Identification of a Novel Luminal Molecular Subtype of Breast Cancer
por: Dvorkin-Gheva, Anna, et al.
Publicado: (2014)

Hormone Receptor and ERBB2 Status in Gene Expression Profiles of Human Breast Tumor Samples
por: Dvorkin-Gheva, Anna, et al.
Publicado: (2011)

Monoamine oxidase-A activity is required for clonal tumorsphere formation by human breast tumor cells
por: Gwynne, William D., et al.
Publicado: (2019)

A target based approach identifies genomic predictors of breast cancer patient response to chemotherapy
por: Hallett, Robin M, et al.
Publicado: (2012)

Serotonin transporter antagonists target tumor-initiating cells in a transgenic mouse model of breast cancer
por: Hallett, Robin M., et al.
Publicado: (2016)

Claudin-low breast cancers: clinical, pathological, molecular and prognostic characterization
por: Sabatier, Renaud, et al.
Publicado: (2014)

An algorithm to discover gene signatures with predictive potential
por: Hallett, Robin M, et al.
Publicado: (2010)

Targeting PVT1 Exon 9 Re-Expresses Claudin 4 Protein and Inhibits Migration by Claudin—Low Triple Negative Breast Cancer Cells
por: Levine, Fayola, et al.
Publicado: (2021)

Claudins in Renal Physiology and Pathology
por: Prot-Bertoye, Caroline, et al.
Publicado: (2020)

Research progress of Claudin-low breast cancer
por: Pan, Chenglong, et al.
Publicado: (2023)

Kaiso depletion attenuates the growth and survival of triple negative breast cancer cells
por: Bassey-Archibong, Blessing I, et al.
Publicado: (2017)

E2F1 and KIAA0191 expression predicts breast cancer patient survival
por: Hallett, Robin M, et al.
Publicado: (2011)

Antagonists of the serotonin receptor 5A target human breast tumor initiating cells
por: Gwynne, William D., et al.
Publicado: (2020)

Estrogen independent gene expression defines clinically relevant subgroups of estrogen receptor positive breast cancer
por: Hallett, Robin M, et al.
Publicado: (2014)

EMT Features in Claudin-Low versus Claudin-Non-Suppressed Breast Cancers and the Role of Epigenetic Modifications
por: Voutsadakis, Ioannis A.
Publicado: (2023)

Differential response to exercise in claudin-low breast cancer
por: Glass, Oliver K., et al.
Publicado: (2017)

Severe, but not moderate asthmatics share blood transcriptomic changes with post-traumatic stress disorder and depression
por: Haas-Neil, Sandor, et al.
Publicado: (2022)

A virtual library for behavioral performance in standard conditions—rodent spontaneous activity in an open field during repeated testing and after treatment with drugs or brain lesions
por: Szechtman, Henry, et al.
Publicado: (2022)

Re-definition of claudin-low as a breast cancer phenotype
por: Fougner, Christian, et al.
Publicado: (2020)

Total particulate matter concentration skews cigarette smoke's gene expression profile
por: Dvorkin-Gheva, Anna, et al.
Publicado: (2016)

Expression of claudin-5, claudin-7 and occludin in oral squamous cell carcinoma and their clinico-pathological significance
por: Phattarataratip, Ekarat, et al.
Publicado: (2016)

Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
por: Prat, Aleix, et al.
Publicado: (2010)

Prognostic Significance of Low Claudin3 Expression in Luminal Breast Cancers
por: Mudduwa, Lakmini, et al.
Publicado: (2017)

Claudin 1 in Breast Tumorigenesis: Revelation of a Possible Novel “Claudin High” Subset of Breast Cancers
por: Myal, Yvonne, et al.
Publicado: (2010)

Effects of Two Distinct Psychoactive Microbes, Lacticaseibacillus rhamnosus JB-1 and Limosilactobacillus reuteri 6475, on Circulating and Hippocampal mRNA in Male Mice
por: Haas-Neill, Sandor, et al.
Publicado: (2022)

DOCK1 Regulates Growth and Motility through the RRP1B-Claudin-1 Pathway in Claudin-Low Breast Cancer Cells
por: Chiang, Shih-Kai, et al.
Publicado: (2019)

Treatment-induced cell cycle kinetics dictate tumor response to chemotherapy
por: Hallett, Robin M., et al.
Publicado: (2015)

Virus-Intrinsic Differences and Heterogeneous IRF3 Activation Influence IFN-Independent Antiviral Protection
por: Hare, David N., et al.
Publicado: (2020)

The claudins
por: Lal-Nag, Madhu, et al.
Publicado: (2009)

Detection of Increased Expression of Claudin-1 in Triple-Negative Breast Cancer: Analysis and Clinical-Pathological Correlation
por: Ouban, Abderrahman, et al.
Publicado: (2023)

Topsentinol L Trisulfate, a Marine Natural Product That Targets Basal-like and Claudin-Low Breast Cancers
por: El-Chaar, Nader N., et al.
Publicado: (2021)

Claudin 1 in Breast Cancer: New Insights
por: Zhou, Bowen, et al.
Publicado: (2015)

Inhibition of proliferation and migration of luminal and claudin-low breast cancer cells by PDGFR inhibitors
por: Stalker, Leanne, et al.
Publicado: (2014)

Neuropilin-1 is over-expressed in claudin-low breast cancer and promotes tumor progression through acquisition of stem cell characteristics and RAS/MAPK pathway activation
por: Tang, Yu Hin, et al.
Publicado: (2022)

Regulation of claudins in blood-tissue barriers under physiological and pathological states
por: Gonçalves, Andreia, et al.
Publicado: (2013)

All Benign and Malignant Apocrine Breast Lesions Over-Express Claudin 1 and 3 and Are Negative for Claudin 4
por: Shousha, Sami, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_p4d42po8l1om7ifnel130rrkat